Dietrich Huppe
Overview
Explore the profile of Dietrich Huppe including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
485
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huppe D, Serfert Y, Cornberg M, Wedemeyer H
Z Gastroenterol
. 2024 Nov;
63(1):31-38.
PMID: 39586812
In 2016, the World Health Organization (WHO) decided on an initiative to identify 90% of the world's existing hepatitis B and C virus infections by 2030, treat 80% and reduce...
2.
Cornberg M, Huppe D, Sarrazin C, Ahumada A, Jorquera Plaza F, Marino Z, et al.
Adv Ther
. 2024 Oct;
41(12):4669-4682.
PMID: 39470876
Introduction: This brief report presents updated findings from the previously published CREST study evaluating the safety and effectiveness of 8-week glecaprevir/pibrentasvir (GLE/PIB) in treatment-naïve patients with chronic hepatitis C virus...
3.
Lugnier C, Sommerlatte S, Attenberger U, Beer A, Bentz M, Benz S, et al.
Oncol Res Treat
. 2024 Mar;
47(6):296-305.
PMID: 38484712
In the context of the COVID-19 pandemic, there has been a scarcity of resources with various effects on the care of cancer patients. This paper provides an English summary of...
4.
Huppe D, Wedemeyer H, Cornberg M
J Hepatol
. 2023 Nov;
80(4):e174-e176.
PMID: 37926117
No abstract available.
5.
Reinacher-Schick A, Ebert M, Piso P, Huppe D, Schmitt J, Schildmann J
Dtsch Arztebl Int
. 2023 Jul;
120(33-34):545-552.
PMID: 37427989
Background: During the COVID-19 pandemic, there was a decrease in the rates of diagnosis and treatment of cancer. However, only a few detailed analyses have been made to date regarding...
6.
van Bommel F, Stein K, Heyne R, Petersen J, Buggisch P, Berg C, et al.
J Hepatol
. 2023 Apr;
78(5):926-936.
PMID: 37062574
Background & Aims: Nucleos(t)ide analogues (NUCs) are the standard and mostly lifelong treatment for chronic HBeAg-negative hepatitis B, as functional cure (loss of HBsAg) is rarely achieved. Discontinuation of NUC...
7.
Heil F, Aschenbeck J, Huppe D
Dtsch Med Wochenschr
. 2023 Jan;
148(3):77-84.
PMID: 36690003
20 years of colonoscopy for early cancer detection and screening in Germany. A success story - there is no longer any doubt about that, but a critical look should not...
8.
Tacke F, Klinker H, Boeker K, Merle U, Link R, Buggisch P, et al.
Hepatol Commun
. 2022 Jun;
6(9):2488-2495.
PMID: 35666055
While direct-acting antivirals (DAAs) cure chronic hepatitis C virus (HCV) infection in almost all patients, some patients remain at risk of liver disease despite HCV cure. In order to identify...
9.
Cornberg M, Ahumada A, Aghemo A, Andreoni M, Bhagat A, Butrymowicz I, et al.
Adv Ther
. 2022 May;
39(7):3146-3158.
PMID: 35543964
Introduction: In clinical trials with hepatitis C virus-infected treatment-naïve (TN) patients with compensated cirrhosis (CC), glecaprevir/pibrentasvir (G/P), a fixed-dose, once-daily, pangenotypic regimen, has demonstrated sustained virologic response at posttreatment Week...
10.
Huppe D, Stoehr A, Buggisch P, Mauss S, Klinker H, Teuber G, et al.
J Viral Hepat
. 2021 Aug;
28(10):1474-1483.
PMID: 34339561
The number of patients diagnosed with hepatitis C virus (HCV) is markedly higher than the number initiating treatment indicating gaps in the care cascade, likely centred around reaching at-risk populations....